Trial Profile

A Phase 2, Two-Stage, Serial Cohort Dose Escalation and Expansion Study of a Single Intravenous Infusion of HBI 3000 for the Conversion of Atrial Fibrillation (AF) of Recent Onset

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sulcardine (Primary)
Indications Atrial fibrillation
Focus Adverse reactions; Therapeutic Use
Acronyms HBI-3000-402
Sponsors HUYA Bioscience International

Most Recent Events

24 Apr 2025 According to HUYABIO International media release media release, initial clinical safety and efficacy results for HBI-3000 will be highlighted in a poster presentation at the Heart Rhythm Annual Meeting to be held April 24 - 27 in San Diego, CA.
24 Apr 2025 Results presented in a HUYABIO International media release.
07 Jan 2025 Planned End Date changed from 1 Dec 2024 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com